98550-19-7

Usage

Uses

Used in Pharmaceutical Industry:
6-(Methylthio)pyrimido[5,4-d]pyrimidin-4(1H)-one is used as a potential anti-cancer agent for its ability to inhibit the growth of cancer cells by targeting the CDC25 phosphatase family. This makes it a promising candidate for the development of new cancer therapies.
Used in Medicinal Chemistry Research:
6-(Methylthio)pyrimido[5,4-d]pyrimidin-4(1H)-one is used as a subject of study for its pharmacological activities, including its potential as an anti-tumor and anti-inflammatory agent. Its unique chemical structure provides a basis for further exploration in the field of drug discovery.
Used in Drug Development:
6-(Methylthio)pyrimido[5,4-d]pyrimidin-4(1H)-one is utilized in the development of new drugs, particularly those aimed at treating cancer. Its potential to target specific cellular processes involved in tumor growth positions it as a valuable component in the creation of novel therapeutic agents.

InChI:InChI=1/C7H6N4OS/c1-13-7-8-2-4-5(11-7)6(12)10-3-9-4/h2-3H,1H3,(H,9,10,12)

Upstream product

• 100130-05-0 5-amino-2-methylsulfanylpyrimidine-4-carboxylic acid 
• 7518-70-9 1-ethoxyethanol 
• 3473-63-0 formamidine acetic acid 
• 110-80-5 2-ethoxy-ethanol 
• 50593-92-5 5-bromo-2-methylsulfanyl-pyrimidine-4-carboxylic acid 
• 64-18-6 formic acid 
• 77287-34-4 formamide 

Downstream Products

• 177908-24-6 4-[(3-Chloro-4-fluoro-phenyl)amino]-6-methylthio-pyrimido[5,4-d]pyrimidine 
• 176637-10-8 4-chloro-6-methylthio-pyrimido[5,4-d]pyrimidine 
• 1213249-79-6 C₂₃H₁₉F₃N₆O₂S 
• 1213250-28-2 C₂₇H₃₁N₇O₄S₂ 
• 1213249-80-9 C₁₆H₁₅N₅O₂S 
• 1213249-88-7 C₁₅H₁₃N₅O₂S 

Relevant academic research and scientific papers

Pyrimido [5, 4-d] pyrimidines, pharmaceuticals containing these compounds, their use and processes for their preparation

Pyrimido[5,4-d]pyrimidines of the general formula [Figure] which have an inhibitory effect on signal transduction mediated by tyrosine kinases, their use for the treatment of oncoses, and their preparation. Exemplary compounds are: (a) 4-(5-indolylamino)-6-morpholinopyrimido[5,4-d]pyrimidine; (b) 4-(5-indolylamino)-6-[trans-(4-hydroxycyclohexyl)amino]pyrimido[5,4-d]pyrimidine; (c) 4-[(3-chloro-4-fluorophenyl)amino]-6-[4-(morpholinocarbonylmethyl)-1-piperazinyl]pyrimido[5,4-d]pyrimidine; (d) 4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-morpholinyl)amino]pyrimido[5,4-d]pyrimidine; (e) 4-[(3-chloro-4-fluorophenyl)amino]-6-(4-picolylamino)pyrimido[5,4-d]pyrimidine; (f) 4-[(3-chloro-4-fluorophenyl)amino]-6-[1-trifluoroacetyl-4-piperidinylamino]pyrimido[5,4-d]pyrimidine; (g) 4-[(3-chloro-4-fluorophenyl)amino]-6-(endo-tropinylamino)pyrimido[5,4-d]pyrimidine; and, (h) 4-[(3-chloro-4-fluorophenyl)amino]-6-(exo-tropinylamino)pyrimido[5,4-d]pyrimidine.

Pyrimido[5,4]-dipyrimidines, pharmaceuticals containing them, their use and processes for the preparation thereof

Pyrimido[5,4-d]pyrimidines of the general formula [Figure] which have an inhibitory effect on signal transduction mediated by tyrosine kinases, their use for the treatment of disorders, in particular of oncoses, and their preparation. Exemplary compounds are: 4-[(3-Chloro-4-fluorophenyl)amino]-6-[1-methyl-4-piperidinylamino]pyrimido[5,4-d]pyrimidine, and 4-[(3-Chloro-4-fluorophenyl)amino]-6-[trans-4-dimethyl-aminocycohexylamino]pyrimido[5,4-d]pyrimidine.